Cantor Fitzgerald reissued their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a research note published on Tuesday, May 7th, AnalystRatings.com reports.
“: We reiterate our Overweight rating and $13 price target. We believe Seres is at the forefront of unlocking the potential for microbiome modulation to generate novel methods by which to treat medical conditions. Continuing with the company’s re-prioritization, Seres announced modifications to the ongoing SER-109 Phase 3 trial to potentially accelerate the top-line data readout. We believe recovery of the stock could be supported by this and the other recent changes that may expedite data demonstrating that microbiome-based therapies have their desired effects.”,” Cantor Fitzgerald’s analyst commented.
Several other equities research analysts also recently issued reports on the company. Cowen reiterated a buy rating on shares of Seres Therapeutics in a report on Tuesday, May 7th. HC Wainwright reiterated a buy rating and set a $8.00 price target on shares of Seres Therapeutics in a report on Friday, May 3rd. BidaskClub downgraded Seres Therapeutics from a hold rating to a sell rating in a report on Friday, May 3rd. Chardan Capital restated a buy rating and issued a $15.00 price objective on shares of Seres Therapeutics in a research note on Thursday, May 2nd. Finally, Jefferies Financial Group began coverage on Seres Therapeutics in a research note on Tuesday, April 30th. They issued a hold rating and a $7.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $11.13.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.12). Seres Therapeutics had a negative return on equity of 1,583.95% and a negative net margin of 301.60%. The company had revenue of $7.32 million for the quarter, compared to the consensus estimate of $8.61 million. On average, equities analysts expect that Seres Therapeutics will post -1.83 EPS for the current year.
A number of large investors have recently made changes to their positions in the business. DekaBank Deutsche Girozentrale grew its stake in Seres Therapeutics by 21.5% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 3,500 shares during the period. BNP Paribas Arbitrage SA grew its stake in Seres Therapeutics by 945.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,339 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 3,924 shares during the period. Bank of New York Mellon Corp grew its stake in Seres Therapeutics by 7.6% in the 4th quarter. Bank of New York Mellon Corp now owns 85,364 shares of the biotechnology company’s stock valued at $386,000 after purchasing an additional 6,023 shares during the period. State of Wisconsin Investment Board grew its stake in Seres Therapeutics by 30.0% in the 1st quarter. State of Wisconsin Investment Board now owns 27,700 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 6,400 shares during the period. Finally, Great West Life Assurance Co. Can bought a new position in Seres Therapeutics in the 4th quarter valued at $30,000. Hedge funds and other institutional investors own 82.03% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Read More: Trading on Margin
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.